Exciting Advances in mRNA Therapy at ASH Annual Meeting
Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a pioneering force in mRNA cell therapy targeting autoimmune diseases, is set to present safety and tolerability data from their flagship therapy, Descartes-08. This data will be showcased at the renowned 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which takes place in San Diego. The event is scheduled from December 7-10, and Cartesian's findings promise to make a significant impact in the field.
About Descartes-08
Descartes-08 is an innovative mRNA-engineered chimeric antigen receptor T-cell (mRNA CAR-T) therapy specifically developed to address the challenges posed by multiple myeloma and certain autoimmune diseases. This cutting-edge therapy is designed not just to fight these conditions but also to enhance patient safety and comfort. Unlike traditional DNA-based CAR T-cell therapies, Descartes-08 can be administered without the need for chemotherapy, offering a more convenient outpatient option.
Details of the Presentation
During the ASH Annual Meeting, Cartesian Therapeutics will present crucial details surrounding their clinical work:
- Publication Number: 2080
- Title: Safety and Tolerability of BCMA-Directed mRNA CAR T-Cell Therapy in Multiple Myeloma and Autoimmune Diseases
- Presenter: Dr. Miloš Miljkovi?, Chief Medical Officer, Cartesian Therapeutics
- Session Name: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster I
- Session Date/Time: Saturday, December 7, from 5:30 PM to 7:30 PM PT
- Location: San Diego Convention Center, Halls G-H
Highlighted Inclusion
In an exciting development, the poster detailing this important research has also been selected for the ASH Poster Walk, an event dedicated to presenting notable advances in blood research. This takes place on December 9 at 7:30 AM PT in the Blood Journal Studio within the Poster Hall.
Exploring the Significance of Descartes-08
The significance of Descartes-08 extends beyond traditional therapies, as this mRNA CAR-T approach focuses on targeting the B-cell maturation antigen (BCMA). The therapy is currently in clinical development to treat conditions like generalized myasthenia gravis (MG) and systemic lupus erythematosus. Its design aims to minimize risks associated with genomic integration, which can lead to cancer. This innovative method has already received both Orphan Drug Designation and Regenerative Medicine Advanced Therapy Designation from the FDA, reflecting its potential to address unmet medical needs.
About Cartesian Therapeutics
Cartesian Therapeutics stands at the forefront of biotech innovation, specializing in mRNA therapies for autoimmune diseases. The company’s initiatives are geared towards advancing patient care through cutting-edge treatment options. Descartes-08 is currently in Phase 2b trials for MG and is also under development for systemic lupus erythematosus, with additional trials planned for other autoimmune conditions. Their pipeline further includes Descartes-15, an advanced anti-BCMA mRNA CAR-T therapy, signaling promising advancements in this therapeutic area.
Investor and Media Contact Information
If you would like to learn more about Cartesian Therapeutics or inquire about investments, the company is open to communications. Investors can reach out to Melissa Forst at Argot Partners, and for media inquiries, David Rosen is available through the same firm.
Frequently Asked Questions
What is Cartesian Therapeutics known for?
Cartesian Therapeutics focuses on developing mRNA therapies for autoimmune diseases, with a strong emphasis on innovative treatments that enhance patient safety.
What is Descartes-08?
Descartes-08 is an mRNA-engineered chimeric antigen receptor T-cell therapy designed to treat multiple myeloma and autoimmune diseases, offering a safer alternative to traditional therapies.
When is the ASH Annual Meeting?
The ASH Annual Meeting is scheduled for December 7-10, where Cartesian Therapeutics will present critical safety and tolerability data from their ongoing clinical studies.
What are the benefits of mRNA CAR-T therapies?
mRNA CAR-T therapies like Descartes-08 do not require preconditioning chemotherapy and aim to reduce the risks associated with genomic integration in patients.
How can I get in touch with Cartesian Therapeutics?
For investor relations, contact Melissa Forst at Argot Partners. Media inquiries can be directed to David Rosen through the same agency.
